earn anoth result
move piec normal
organ growth adjust fire impact solid beat howev
market accustom bigger upsid bit nois quarter plu
above-averag valuat surpris stock today step back
think stori remain intact robust biopharma continu driven bioproduct
china structur strong b/ readi deploy scale continu
support share gain dont expect return
replic see mid-teen return via organ growth low teen ep growth
take quarter
data center fire creat nois organ drag mostli analyt instrument
lab products/dx driver remain robust biopharma grew dd
bioproduct china mid-teen growth industrial/appli grew lsd
though msd ex fire still repres stack deceler recent
lap feic strength key factor academic/gov flat stack
look stabl tough comp segment lss driver organ biopharma
comp issu lp grew ex fire rel stabl stack basi
bioproduct remain robust good
outgrow peer china said mid-teen growth keep posit tone given
littl exposur china generics/food test read
chroma/mass spec strong hard make read a/wat flag
small molecul weak sinc seen speak share gain and/or
big small show deceler industrial/instru
could constru neg industrial/instru orient peer pki
yet ex tough feic comp fire drag see chang trend
valuat rais pt
rais pt use ntm price-to-earnings vs current
assum continu organ growth plu success enabl slight multipl
expans pt support dcf
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jul edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
million us except per share amount
good
interest expens incom
net incom continu op
million us except per share amount
good
interest expens incom
net incom continu op
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
rais pt use ntm price-to-earnings vs current
assum continu organ growth plu success enabl slight
multipl expans pt support dcf
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
includ biopharma slow chines economi
risk
integr recent larg make bad strateg decis futur
